PROVENGE sipuleucel-T mechanism of action for advanced prostate cancer uses a patient's own immune cells for treatment.
Schematic of mesoporous silica rod (MSR)-based vaccine in situ self-assembly and mechanism of action. MSRs dispersed in phosphate-buffered saline (PBS) are injected subcutaneously, forming a pocket. As PBS diffuses away from the site of injection, MSRs randomly and spontaneously self-assemble ...
Sipuleucel-T immunotherapy for castrate-resistant prostate cancer modulates soluble B7-H3: A novel mechanism of actiondoi:10.1016/S1569-9056(18)31446-5A. ChangS. NairD. GeorgeB. InmanElsevier ScienceEuropean Urology Supplements
of Provenge may include, but are not limited to, the following:•Chills•Fatigue•Fever•Back pain•Nausea•Joint ache•HeadacheMechanism of ActionDendreon is an autologous cellular immunotherapy. While the precise mechanism of action is unknown, Provenge is designed to induce an immune ...
Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clinically relevant immune response, and the observed efficacy in Phase III trials in 'early' or asymptomatic or minimally symptomatic mCRPC. There are three broad ...
Additional trials are aiming to expand the application of sipuleucel-T to prostate cancer patients beyond the mCRPC setting. Ongoing challenges include understanding the full mechanism of action of sipuleucel-T, optimizing the sequence of sipuleucel-T in relation to other therapies for mCRPC in ...
We found that sipuleucel-T's FDA approval was delayed by 3years, reportedly because of the vaccine's new mechanism of action. Sipuleucel-T was cleared by the European Medicines Agency 2years later, but other national agencies were not approached. It was priced at $US93,000 for a course ...
Evidence of antigen spread after treatment may not only provide insights into the mechanism of action (MoA) of cancer immunotherapies, but also provide pharmacodynamic (post-treatment) biomarkers of clinical response and outcome. Sipuleucel-T , an FDA approved autologous cellular immunotherapy for the ...
BACKGROUND: Sipuleucel-T is a US Food and Drug Administration-approved immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Its mechanism of action is not fully understood. This prospective trial evaluated the direct immune effects of systemically...
Adverse events in all four of these studies centered around cytokine release. This paper also reviews a Phase II study of sipuleucel-T given neoadjuvantly that speaks to its mechanism of action. Additionally, there is a registry study of sipuleucel-T that has been ...